CDK1 and colorectal cancer: Zhu et al. stated that an elevated expression level of CDK1 correlates with poor clinical outcomes in colorectal cancer and that inhibiting CDK1 increases 5-fluorouracil sensitivity index in patients suffering from colorectal cancer [71].